Troy Edward Wilson, President and CEO of Kura Oncology ($KURA), bought about 713 thousand dollars worth of $KURA shares in three open market transactions over the past year, with his most recent purchase on September 8, 2025. These purchases rank 677th among 4,983 insiders, below the average of 1.46 million dollars per buyer. As a director, he sold 5.75 million dollars of Avidity Biosciences ($RNAM) shares in eight transactions, most recently on September 5, 2025, ranking 1,747th out of 11,678 insiders with sales averaging 8.59 million dollars across 6.37 trades. Wilson also sold 327 thousand dollars of $KURA on September 29, 2025, and 37 thousand dollars of Puma Biotechnology ($PBYI) on June 13, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 23, 2026 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | M | Common Stock | 6103 | $6.15 | 1,014,650.0000 | 87,645,000 | 0.61% | 0.01% |
| March 23, 2026 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | M | Stock Option (Right to Buy) | 6103 | $0.00 | 0.0000 | 87,645,000 | 0.00% | 0.01% |
| Feb. 27, 2026 | Atrium Therapeutics, Inc. | $RNA | WILSON TROY EDWARD | Not found | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Not found | D | Common Stock | 65091 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.04% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Not found | D | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.01% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Not found | D | Stock Option (Right to Buy) | 13489 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.01% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Not found | D | Stock Option (Right to Buy) | 10034 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.01% |
| Feb. 27, 2026 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Not found | D | Common Stock | 13711 | $0.00 | 0.0000 | 150,675,742 | 100.00% | 0.01% |
| Jan. 2, 2026 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | A | Option to purchase common stock | 1120000 | $0.00 | 1,120,000.0000 | 87,645,000 | 9999.99% | 1.28% |
| Nov. 13, 2025 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | A | Common Stock | 182500 | $0.00 | 1,008,547.0000 | 87,645,000 | 22.09% | 0.21% |
| Sept. 27, 2025 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | A | Common Stock | 182500 | $0.00 | 862,662.0000 | 86,161,000 | 26.83% | 0.21% |
| Sept. 29, 2025 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | S | Common Stock | 36615 | $8.94 | 826,047.0000 | 86,161,000 | 4.24% | 0.04% |
| Sept. 5, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | S | Common Stock | 14500 | $50.00 | 83,136.0000 | 120,212,301 | 14.85% | 0.01% |
| Sept. 5, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | M | Stock Option (Right to Buy) | 14500 | $0.00 | 0.0000 | 120,212,301 | 100.00% | 0.01% |
| Sept. 5, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | M | Common Stock | 14500 | $12.48 | 97,636.0000 | 120,212,301 | 17.44% | 0.01% |
| Sept. 5, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | S | Common Stock | 15000 | $50.00 | 68,136.0000 | 120,212,301 | 18.04% | 0.01% |
| Sept. 8, 2025 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President & CEO | P | Common Stock | 50000 | $8.20 | 680,162.0000 | 86,161,000 | 7.93% | 0.06% |
| Aug. 12, 2025 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | P | Common Stock | 36506 | $5.85 | 616,668.0000 | 86,161,000 | 6.29% | 0.04% |
| Aug. 13, 2025 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | P | Common Stock | 13494 | $6.64 | 630,162.0000 | 86,161,000 | 2.19% | 0.02% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | S | Common Stock | 15000 | $45.00 | 712,390.0000 | 120,212,301 | 2.06% | 0.01% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | M | Common Stock | 22000 | $12.03 | 734,390.0000 | 120,212,301 | 3.09% | 0.02% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | S | Common Stock | 22000 | $45.00 | 712,390.0000 | 120,212,301 | 3.00% | 0.02% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | M | Common Stock | 7500 | $12.48 | 719,890.0000 | 120,212,301 | 1.05% | 0.01% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | S | Common Stock | 7500 | $45.00 | 712,390.0000 | 120,212,301 | 1.04% | 0.01% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | S | Common Stock | 15000 | $45.00 | 712,390.0000 | 120,212,301 | 2.06% | 0.01% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | S | Common Stock | 17777 | $45.00 | 712,390.0000 | 120,212,301 | 2.43% | 0.01% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | S | Common Stock | 17777 | $45.00 | 712,390.0000 | 120,212,301 | 2.43% | 0.01% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | M | Stock Option (Right to Buy) | 22000 | $0.00 | 0.0000 | 120,212,301 | 100.00% | 0.02% |
| Aug. 6, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | M | Stock Option (Right to Buy) | 7500 | $0.00 | 14,500.0000 | 120,212,301 | 34.09% | 0.01% |
| June 13, 2025 | PUMA BIOTECHNOLOGY, INC. | $PBYI | WILSON TROY EDWARD | Director | S | Common Stock | 10800 | $3.40 | 44,100.0000 | 49,100,433 | 19.67% | 0.02% |
| June 11, 2025 | PUMA BIOTECHNOLOGY, INC. | $PBYI | WILSON TROY EDWARD | Director | A | Common Stock | 27000 | $0.00 | 54,900.0000 | 49,100,433 | 96.77% | 0.05% |
| June 10, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | A | Stock Option (Right to Buy) | 10034 | $0.00 | 10,034.0000 | 120,212,301 | 9999.99% | 0.01% |
| June 10, 2025 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | A | Common Stock | 6692 | $0.00 | 69,425.0000 | 120,212,301 | 10.67% | 0.01% |
| Jan. 2, 2025 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | A | Option to purchase common stock | 625000 | $0.00 | 625,000.0000 | 86,161,000 | 9999.99% | 0.73% |
| June 18, 2024 | PUMA BIOTECHNOLOGY, INC. | $PBYI | WILSON TROY EDWARD | Director | A | Common Stock | 27000 | $0.00 | 27,900.0000 | 47,550,852 | 3000.00% | 0.06% |
| June 13, 2024 | PUMA BIOTECHNOLOGY, INC. | $PBYI | WILSON TROY EDWARD | Director | S | Common Stock | 27000 | $3.33 | 900.0000 | 47,550,852 | 96.77% | 0.06% |
| June 13, 2024 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | A | Stock Option (Right to Buy) | 13489 | $0.00 | 13,489.0000 | 0 | 9999.99% | 0.00% |
| Jan. 24, 2024 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | S | Common Stock | 84107 | $20.23 | 579,753.0000 | 73,229,000 | 12.67% | 0.11% |
| Jan. 24, 2024 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | M | Common Stock | 84107 | $6.15 | 663,860.0000 | 73,229,000 | 14.51% | 0.11% |
| Jan. 24, 2024 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | S | Common Stock | 6945 | $20.23 | 579,753.0000 | 73,229,000 | 1.18% | 0.01% |
| Jan. 24, 2024 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | M | Common Stock | 6945 | $4.80 | 586,698.0000 | 73,229,000 | 1.20% | 0.01% |
| Jan. 2, 2024 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | A | Option to purchase common stock | 560000 | $0.00 | 560,000.0000 | 73,229,000 | 9999.99% | 0.76% |
| Dec. 12, 2023 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | J | Common Stock | 250000 | $0.00 | 771,252.0000 | 0 | 47.96% | 0.00% |
| Dec. 12, 2023 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | J | Common Stock | 300000 | $0.00 | 1,021,252.0000 | 0 | 22.71% | 0.00% |
| Dec. 12, 2023 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | J | Common Stock | 300000 | $0.00 | 771,252.0000 | 0 | 63.66% | 0.00% |
| Dec. 12, 2023 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | J | Common Stock | 250000 | $0.00 | 771,252.0000 | 0 | 24.48% | 0.00% |
| Dec. 7, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | G | Common Stock | 2000 | $0.00 | 579,753.0000 | 66,990,000 | 0.34% | 0.00% |
| Dec. 7, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | G | Common Stock | 1000 | $0.00 | 579,753.0000 | 66,990,000 | 0.17% | 0.00% |
| June 15, 2023 | Avidity Biosciences, Inc. | $RNAM | WILSON TROY EDWARD | Director | A | Stock Option (Right to Buy) | 22000 | $0.00 | 22,000.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2023 | PUMA BIOTECHNOLOGY, INC. | $PBYI | WILSON TROY EDWARD | Director | A | Common Stock | 27000 | $0.00 | 27,900.0000 | 44,929,998 | 3000.00% | 0.06% |
| June 13, 2023 | PUMA BIOTECHNOLOGY, INC. | $PBYI | WILSON TROY EDWARD | Director | S | Common Stock | 27000 | $3.45 | 900.0000 | 44,929,998 | 96.77% | 0.06% |
| June 2, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 8394 | $0.00 | 582,753.0000 | 66,990,000 | 1.42% | 0.01% |
| June 2, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 8394 | $0.00 | 1,436,571.0000 | 66,990,000 | 0.59% | 0.01% |
| June 2, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 41318 | $0.00 | 1,395,253.0000 | 66,990,000 | 2.88% | 0.06% |
| June 2, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 212500 | $0.00 | 1,182,753.0000 | 66,990,000 | 15.23% | 0.32% |
| June 2, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 300000 | $0.00 | 882,753.0000 | 66,990,000 | 25.36% | 0.45% |
| June 2, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 300000 | $0.00 | 582,753.0000 | 66,990,000 | 33.98% | 0.45% |
| June 2, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 300000 | $0.00 | 582,753.0000 | 66,990,000 | 106.10% | 0.45% |
| June 2, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 27966 | $0.00 | 582,753.0000 | 66,990,000 | 4.58% | 0.04% |
| Feb. 16, 2023 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | A | Option to purchase common stock | 560000 | $0.00 | 560,000.0000 | 66,990,000 | 9999.99% | 0.84% |
| Aug. 19, 2022 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 11985 | $0.00 | 1,164,537.0000 | 0 | 1.02% | 0.00% |
| Oct. 6, 2022 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 1084300 | $0.00 | 1,164,537.0000 | 0 | 1351.37% | 0.00% |
| Oct. 6, 2022 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 1084300 | $0.00 | 1,164,537.0000 | 0 | 48.22% | 0.00% |
| Aug. 19, 2022 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 41318 | $0.00 | 80,237.0000 | 0 | 106.16% | 0.00% |
| Aug. 19, 2022 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 41318 | $0.00 | 2,248,837.0000 | 0 | 1.80% | 0.00% |
| Aug. 19, 2022 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 17708 | $0.00 | 2,290,155.0000 | 0 | 0.77% | 0.00% |
| July 14, 2022 | Kura Oncology, Inc. | $KURA | WILSON TROY EDWARD | President and CEO | J | Common Stock | 468297 | $0.00 | 2,307,863.0000 | 0 | 16.87% | 0.00% |